Siemens Healthineers Shares Hit 52-Week Low as Citi Cuts Forecast

Siemens Healthineers AG shares (ETR:SHL) fell 0.95% to €40.47 today, after touching a new 52-week low of €40.32 earlier in the session. The decline extends a difficult 12-month period for the German medical technology giant, with the stock now down 30% over the past year as a confluence of analyst downgrades, strategic uncertainty, and operational challenges weighs on market sentiment.

The latest pressure came from Citi, which lowered its price target on Siemens Healthineers to €59 from €60 while maintaining a Buy rating on the shares. The modest reduction reflects growing caution about the company’s near-term prospects, even as the bank continues to see long-term value in the stock. At current levels, Citi’s target implies potential upside of roughly 46%, though markets appear increasingly skeptical of such optimism.

The downward trajectory has been exacerbated by more substantial analyst moves in recent weeks. Deutsche Bank downgraded the stock from Buy to Hold and slashed its price target to €46 from €57, citing prolonged share-price pressure stemming from parent company Siemens AG’s plan to reduce its stake from 67% to approximately 30% through a targeted spin-off.

The bank expressed concerns that the lack of definitive timelines for this restructuring could cap the stock’s ability to outperform until the stake-reduction strategy reaches completion. The potential for additional on-market placements even after the planned spin has introduced further uncertainty into an already clouded outlook.

UBS also joined the downgrade cycle, moving Siemens Healthineers to Neutral from Buy on concerns about the Chinese market.

The firm highlighted increasing competition from local firms such as United Imaging and Mindray, which are gaining ground in a market that has historically been a significant growth driver for Western medical equipment manufacturers. Even with anticipated economic stimulus, UBS projects China will deliver only 5% to 10% growth for Siemens Healthineers, a subdued forecast that contrasts sharply with more optimistic consensus expectations.

The operational challenges extend beyond China. In its fiscal 2026 outlook, Siemens Healthineers projected adjusted earnings per share of €2.20 to €2.40, compared with €2.39 in fiscal 2025. The company cited higher tariffs and foreign exchange headwinds as factors expected to weigh on profitability.

Tariff costs, which totaled approximately €200 million in fiscal 2025, are projected to double to about €400 million in 2026, even after mitigation measures. These external pressures have raised questions about the company’s ability to maintain profit margins in an increasingly difficult macroeconomic environment.

The combination of analyst downgrades, parental stake reduction uncertainty, competitive pressures in China, and rising tariff costs has created a perfect storm for Siemens Healthineers shares. Markets appear to be pricing in a prolonged period of uncertainty, with the stock trading well below analyst price targets and showing little sign of finding a floor.